Cvrx, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cvrx, Inc. (CVRX) on September 21, 2026, reporting events occurring on September 16, 2026. The filing addresses Item 5.02 regarding the appointment of a new Chief Financial Officer (CFO) and the departure of the incumbent.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on executive compensation and personnel changes.
Material Changes
The primary material change is the leadership transition in the finance function:
- Appointment: John Landry was appointed as Chief Financial Officer.
- Departure: Jared Oasheim is resigning as CFO, having previously notified the Board of his intention to step down on June 8, 2026.
- Timeline: Mr. Landry's employment commences on October 12, 2026, to facilitate a transition. He will assume full CFO responsibilities the day after the Company files its Form 10-Q for the quarter ending September 30, 2026.
Management Commentary and Compensation
The Compensation Committee approved the following compensation package for Mr. Landry:
- Base Salary: $500,000 annually.
- Cash Incentive: Target award of 50% of base salary (pro-rated for fiscal 2026).
- Equity Awards: Initial grants representing 0.80% of total common shares outstanding as of the commencement date. The mix is 75% stock options and 25% restricted stock units (RSUs), utilizing a 1.5:1 multiple of options to RSUs. These are granted under the Nasdaq inducement grant exemption.
- Other Benefits: Payment of forfeited pro-rated bonus from his current employer (subject to repayment if terminated for cause prior to the first anniversary) and reimbursement of travel expenses.
- Severance: Standard executive officer severance agreement.
Mr. Landry brings experience as CFO of Nyxoah SA (since November 2024) and Vapotherm Inc. (2012–2024), along with prior roles at Medtronic and Salient Surgical Technologies.
Investor Verification Checklist
- Verify the exact date Mr. Landry assumes full CFO duties relative to the Q3 2026 Form 10-Q filing.
- Review the full Offer Letter (Exhibit 10.1) for specific vesting schedules and performance metrics tied to the equity awards.
- Confirm the pro-rata calculation for the 2026 cash incentive award.
- Monitor the transition period between October 12, 2026, and the post-10-Q filing date for any interim financial reporting changes.